Blockade of the PD-1/PD-L1 pathway has been observed to increase B-cell activation, proliferation, and subsequently production of disease-specific autoantibodies including anti-bullous pemphigoid 180 (BP180) antibody, leading to development of bullous pemphigoid [37]. Here, COL17A1 is linked to bullous pemphigoid.